UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Jones JD1, Hamilton BJ, Skopelja S, Rigby WF.
Arthritis & rheumatology (Hoboken, N.J.).Arthritis Rheumatol.2014 Nov;66(11):2938-46. doi: 10.1002/art.38798.
OBJECTIVE: Rituximab (RTX), an anti-CD20 monoclonal antibody, is highly effective in the treatment of several autoimmune diseases. The mechanism by which RTX treatment improves rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis is not easily related to B cell depletio
PMID 25080282

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM1, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Iklé D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
Arthritis & rheumatology (Hoboken, N.J.).Arthritis Rheumatol.2014 Nov;66(11):3151-9. doi: 10.1002/art.38788.
OBJECTIVE: Disease relapses are frequent in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study was undertaken to evaluate outcomes in patients with AAV who are re-treated with rituximab (RTX) and prednisone for severe disease relapses.METHODS: The Rituximab in AAV trial was
PMID 25047592

Walsh M.
Current opinion in nephrology and hypertension.Curr Opin Nephrol Hypertens.2014 Nov;23(6):555-9. doi: 10.1097/MNH.0000000000000058.
PURPOSE OF REVIEW: This article reviews the use of plasma exchange for the treatment of antineutrophil cytoplasm antibody-associated vasculitis (AAV) with a focus on current controversies and knowledge gaps.RECENT FINDINGS: Experimental evidence suggesting that antineutrophil cytoplasm antibodies ar
PMID 25144513